Scientists at the Frederick National Laboratory for Cancer Research (FNL) successfully increased the yield production of a challenging protein used in antibody tests for SARS-CoV-2, the virus behind COVID-19, publishing their findings earlier this month in Protein Expression and Purification. 

Scientists at the Frederick National Laboratory for Cancer Research and investigators across the National Institutes of Health (NIH) have developed a highly specific serology test to determine whether a person has antibodies to SARS-CoV-2, a vital tool to understanding the spread of infection from the virus that causes COVID-19. 

The antiviral treatment remdesivir accelerated recovery time among hospitalized participants with advanced COVID-19 compared to participants who received placebo containing inactive ingredients, according to results of a clinical trial published May 22 in the New England Journal of Medicine.  

As COVID-19 spread around the U.S., health care providers needed guidelines to treat patients—and they needed them fast.

The solution? A website that would house data- and expert-backed clinical treatment guidelines devised by a panel of U.S. physicians, statisticians, and other experts from the National Institutes of Health (NIH), universities, and health care organizations.

The Frederick National Laboratory led a collaborative project to build one, finishing in just two weeks.